Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Nat Rev Drug Discov. 2009 Dec;8(12):959-68. doi: 10.1038/nrd2961.

Lessons from 60 years of pharmaceutical innovation.

Author information

  • Lilly Corporate Center, Indianapolis, Indiana 46285, USA. b.munos@lilly.com

Abstract

Despite unprecedented investment in pharmaceutical research and development (R&D), the number of new drugs approved by the US Food and Drug Administration (FDA) remains low. To help understand this conundrum, this article investigates the record of pharmaceutical innovation by analysing data on the companies that introduced the approximately 1,200 new drugs that have been approved by the FDA since 1950. This analysis shows that the new-drug output from pharmaceutical companies in this period has essentially been constant, and remains so despite the attempts to increase it. This suggests that, contrary to common perception, the new-drug output is not depressed, but may simply reflect the limitations of the current R&D model. The implications of these findings and options to achieve sustainability for the pharmaceutical industry are discussed.

PMID:
19949401
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk